Dwaine F. Emerich
Dwaine F. Emerich has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Gorka Orive
Basque Sustainable Pharmacy & Biotherapy Research Group School of Pharmacy University of the Basque Country (UPV/EHU) Vitoria‐Gasteiz Spain
3 shared publications Christopher Thanos
Cytosolve, Inc., Povidence, RI, USA
2 shared publicationsLars U. Wahlberg
NsGene, Inc., 225 Chapman Street, Providence, RI 02905, USA
2 shared publicationsChristopher G Thanos
1 shared publication- Craig R. Halberstadt
Department of General Surgery, Carolinas Medical Center, Charlotte, NC 28232, USA
1 shared publication Denis Poncelet
ONIRIS, UMR CNRS GEPEA 6144 route de la Géraudière, BP 82225, 44322 Nantes Cedex 3, France
1 shared publication
Latest Publications
- 1 August 2015
- Published by Elsevier in Trends in Pharmacological Sciences
- Vol. 36 (8) , 537-546
Cell encapsulation: technical and clinical advances
- 1 August 2015
- Published by Elsevier in Trends in Pharmacological Sciences
- Vol. 36 (8) , 537-546
Cell encapsulation: technical and clinical advances
- 1 April 2014
- Published by Elsevier in Advanced Drug Delivery Reviews
- Vol. 67-68, 131-141
Encapsulated cell therapy for neurodegenerative diseases: From promise to product
- 1 April 2014
- Published by Elsevier in Advanced Drug Delivery Reviews
- Vol. 67-68, 131-141
Encapsulated cell therapy for neurodegenerative diseases: From promise to product
- 15 December 2010
Nanoparticle-Based Technologies for Treating and Imaging Brain Tumors.
Treating malignant brain tumors is one of the most formidable challenges in oncology. Contemporary treatments are hampered, in large part, by limited drug delivery across the blood-brain barrier (BBB) to the tumor bed. Biomaterials are playing an increasingly important role in developing more effective brain tumor treatments. Specifically, polymer (nano)particles can provide prolonged drug delivery directly to the tumor following direct intracerebral injection, by making them physiochemically able to cross the BBB to the tumor, or by functionalizing the material surface with peptides and ligands allowing the drug-loaded material to be systemically administered but still specifically target the tumor cells or tumor endothelium. As such, biomaterials can serve as targeted delivery devices for both conventional and novel therapies including gene therapy, photodynamic therapy, anti-angiogenic and thermotherapy. Nanoparticles also have the potential to play key roles in the diagnosis and imaging of brain tumors by revolutionizing both preoperative and intraoperative brain tumor delineation, allowing early detection of pre-cancerous cells, and providing real-time, longitudinal, non-invasive monitoring/imaging of the effects of treatment. The continued translation of current research into clinical practice will rely on solving challenges relating to the pharmacology of nanoparticles but it is envisioned that novel biomaterials will ultimately allow clinicians to target tumors and introduce multiple, pharmaceutically relevant entities for simultaneous targeting, imaging, and therapy in a unique and unprecedented manner.
- 15 December 2010
Nanoparticle-Based Technologies for Treating and Imaging Brain Tumors.
Treating malignant brain tumors is one of the most formidable challenges in oncology. Contemporary treatments are hampered, in large part, by limited drug delivery across the blood-brain barrier (BBB) to the tumor bed. Biomaterials are playing an increasingly important role in developing more effective brain tumor treatments. Specifically, polymer (nano)particles can provide prolonged drug delivery directly to the tumor following direct intracerebral injection, by making them physiochemically able to cross the BBB to the tumor, or by functionalizing the material surface with peptides and ligands allowing the drug-loaded material to be systemically administered but still specifically target the tumor cells or tumor endothelium. As such, biomaterials can serve as targeted delivery devices for both conventional and novel therapies including gene therapy, photodynamic therapy, anti-angiogenic and thermotherapy. Nanoparticles also have the potential to play key roles in the diagnosis and imaging of brain tumors by revolutionizing both preoperative and intraoperative brain tumor delineation, allowing early detection of pre-cancerous cells, and providing real-time, longitudinal, non-invasive monitoring/imaging of the effects of treatment. The continued translation of current research into clinical practice will rely on solving challenges relating to the pharmacology of nanoparticles but it is envisioned that novel biomaterials will ultimately allow clinicians to target tumors and introduce multiple, pharmaceutically relevant entities for simultaneous targeting, imaging, and therapy in a unique and unprecedented manner.
- 1 April 2008
- Vol. 10 (2) , 132-9
Multifunctional peptide-based nanosystems for improving delivery and molecular imaging.
Nanotechnology is a multidisciplinary scientific field impacting on various facets of preclinical and clinical research. One of the areas most affected is the development of medical treatments, that is, nanomedicine. In particular, drug delivery is expected to benefit from the unique ability of nanoparticles to selectively target different tissues and cellular compartments. In this review, advances using nanoparticles to improve the delivery of peptides by rendering them more stable, less susceptible to degradation, and able to cross physical barriers that typically restrict circulatory system access are discussed. In addition, the use of peptide-nanoparticle conjugates to target normal and diseased tissues to deliver therapeutic agents or to image them for diagnostic and screening purposes, or both, are highlighted. In the next few years these technologies are expected to allow control of drug delivery, targeting, and imaging that is currently unattainable.
- 1 April 2008
- Vol. 10 (2) , 132-9
Multifunctional peptide-based nanosystems for improving delivery and molecular imaging.
Nanotechnology is a multidisciplinary scientific field impacting on various facets of preclinical and clinical research. One of the areas most affected is the development of medical treatments, that is, nanomedicine. In particular, drug delivery is expected to benefit from the unique ability of nanoparticles to selectively target different tissues and cellular compartments. In this review, advances using nanoparticles to improve the delivery of peptides by rendering them more stable, less susceptible to degradation, and able to cross physical barriers that typically restrict circulatory system access are discussed. In addition, the use of peptide-nanoparticle conjugates to target normal and diseased tissues to deliver therapeutic agents or to image them for diagnostic and screening purposes, or both, are highlighted. In the next few years these technologies are expected to allow control of drug delivery, targeting, and imaging that is currently unattainable.
- 1 September 2007
- Published by American Scientific Publishers in Journal of Biomedical Nanotechnology
- Vol. 3 (3) , 235-244
Role of Nanobiotechnology in Cell-Based Nanomedicine: A Concise Review
- 1 September 2007
- Published by American Scientific Publishers in Journal of Biomedical Nanotechnology
- Vol. 3 (3) , 235-244
Role of Nanobiotechnology in Cell-Based Nanomedicine: A Concise Review